Michael Davidson, NewAmsterdam CEO
NewAmsterdam's bid to revive Amgen cardio drug heads to Nasdaq in Frazier SPAC deal
Five years after Amgen buried its CETP cholesterol drug, a Dutch biotech with hundreds of millions in funding is headed to Wall Street to continue …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
